查找临床试验

已按「白血病」检索,对应国际通用词 leukemia

试验不在中国怎么办?

共找到 1,421 项正在招募的试验

数据更新于 22:08,每 5 分钟自动同步
正在招募不适用NCT02863692

Registry of the German CLL Study Group

Germany

年龄 18 Years – 不限

German CLL Study Group

正在招募I 期NCT06787144

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

Japan

年龄 18 Years – 不限

Enliven Therapeutics

正在招募II 期NCT05442216

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

United States

年龄 18 Years – 不限

Joshua Zeidner

正在招募不适用NCT07313592

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

United States

年龄 不限 – 30 Years

Washington University School of Medicine

正在招募II 期中国有中心NCT07244406

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

China

年龄 3 Years – 25 Years

Hebei Senlang Biotechnology Inc., Ltd.

正在招募不适用NCT03921047

Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

United States

年龄 18 Years – 不限

University of Southern California

正在招募I 期NCT05735184

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

United States

年龄 18 Years – 不限

Kura Oncology, Inc.

正在招募不适用NCT04209244

Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia

Denmark

年龄 1 Year – 45 Years

Copenhagen University Hospital, Rigshospitalet

正在招募III 期NCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

United States、Bosnia and Herzegovina、Bulgaria、Croatia、Hungary 等 8 国

年龄 18 Years – 不限

Grifols Therapeutics LLC

正在招募II 期NCT06184009

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

South Korea

年龄 1 Year – 19 Years

Jae Wook Lee

正在招募II 期中国有中心NCT06530550

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

China

年龄 18 Years – 不限

Institute of Hematology & Blood Diseases Hospital, China

正在招募I 期NCT06429449

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

United States

年龄 18 Years – 80 Years

University of Colorado, Denver